Women with HER2+ breast cancer were more likely to have PR− breast cancer; 66.7% of patients with HER2+ breast cancer had PR− breast cancer compared to 24% of those with HER2− breast cancer (p = 0.001). Here, ERBB2 is linked to breast carcinoma.